U.K. Value-Based Pricing Negotiations Could Help NICE-Rejected Cancer Drugs
11:52 EDT 8 Aug 2012 | Elsevier Business Intelligence
Negotiations will start in September 2012 on a value-based pricing approach for new medicines in the U.K., and on a new PPRS scheme for currently marketed drugs, with a new suggestion: oncologics previously rejected by NICE might be reviewed again un..
Original Article: U.K. Value-Based Pricing Negotiations Could Help NICE-Rejected Cancer Drugs
More From BioPortfolio on "U.K. Value-Based Pricing Negotiations Could Help NICE-Rejected Cancer Drugs"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
